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ABSTRACT
Background
While lymph node metastasis is among the strongest predictors of disease-free and overall
survival for patients with breast cancer, the immunological nature of tumor-draining lymph
nodes is often ignored, and may provide additional prognostic information on clinical outcome.
Methods and Findings
We performed immunohistochemical analysis of 47 sentinel and 104 axillary (nonsentinel)
nodes from 77 breast cancer patients with 5 y of follow-up to determine if alterations in CD4,
CD8, and CD1a cell populations predict nodal metastasis or disease-free survival. Sentinel and
axillary node CD4 and CD8 T cells were decreased in breast cancer patients compared to
control nodes. CD1a dendritic cells were also diminished in sentinel and tumor-involved axillary
nodes, but increased in tumor-free axillary nodes. Axillary node, but not sentinel node, CD4 T
cell and dendritic cell populations were highly correlated with disease-free survival,
independent of axillary metastasis. Immune profiling of ALN from a test set of 48 patients,
applying CD4 T cell and CD1a dendritic cell population thresholds of CD4   7.0% and CD1a  
0.6%, determined from analysis of a learning set of 29 patients, provided significant risk
stratification into favorable and unfavorable prognostic groups superior to clinicopathologic
characteristics including tumor size, extent or size of nodal metastasis (CD4, p , 0.001 and
CD1a, p , 0.001). Moreover, axillary node CD4 T cell and CD1a dendritic cell populations
allowed more significant stratification of disease-free survival of patients with T1 (primary
tumor size 2 cm or less) and T2 (5 cm or larger) tumors than all other patient characteristics.
Finally, sentinel node immune profiles correlated primarily with the presence of infiltrating
tumor cells, while axillary node immune profiles appeared largely independent of nodal
metastases, raising the possibility that, within axillary lymph nodes, immune profile changes
and nodal metastases represent independent processes.
Conclusion
These findings demonstrate that the immune profile of tumor-draining lymph nodes is of
novel biologic and clinical importance for patients with early stage breast cancer.
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Lymph node metastasis is well established among the
strongest prognostic indicators of clinical outcome for
patients with breast cancer [1–3]. The technique of sentinel
lymph node (SLN) biopsy has been rapidly adopted over the
past decade, as it accurately predicts axillary (nonsentinel)
lymph node (ALN) metastasis and therefore identiﬁes women
who may be spared the morbidities of axillary dissection [4,5].
With the growing practice of SLN biopsy, new methods of
lymph node analysis are being developed [3,6–8]. SLN
evaluation by multiple hematoxylin and eosin stained sections
(HES), immunohistochemistry (IHC), and most recently, RT-
PCR for breast cancer-associated gene expression has in-
creased metastasis detection by up to 42% [7,9]. Despite these
technical advances, the prognostic signiﬁcance of isolated
tumor cells and RT-PCR–positive nodes remains inconclusive
and highly debated.
Concurrent advances in pathological analysis of primary
breast tumors have found inﬁltrating immune cells of
prognostic signiﬁcance [10,11]. Detailed histological analyses
identiﬁed tumor-inﬁltrating T lymphocytes and dendritic
cells, with diminished dendritic cell inﬁltration directly
correlated with increased nodal metastasis and poor disease-
free and overall survival [10,12–15]. Decreased circulating T
lymphocyte populations have also been shown to correlate
with poor overall survival [16]. Substantial evidence now exists
showing impairment of the systemic and local immune
response during breast cancer progression [10–17]. However,
it is often overlooked that local tumor-draining nodes are the
immunologically active sites where such immune responses,
including tumor antigen presentation and lymphocyte activa-
tion, should develop. Impairment of the immune response is
likely a critical step in lymph node invasion by tumor, and may
precede microscopic metastasis detection. Indeed, a limited
number of studies suggest that alterations in immune proﬁle,
including CD4 helper and CD8 cytotoxic T lymphocytes and
CD1a dendritic cell populations, occur within the local nodes
of breast cancer patients, although their clinical signiﬁcance
remains unknown [18–20]. Thus, we reasoned that immune
proﬁle analysis of tumor-draining nodes may be a more
sensitive and earlier method of detecting metastasis, and may
provide additional information on clinical outcome.
Materials and Methods
Study patients. Breast cancer patients aged 29–80 years
treated at Stanford University Medical Center between
February 1997 and January 1999 and found to have tumor-
involved SLNs by multilevel HES or IHC were evaluated.
PatientswhosubsequentlyunderwentALNdissection(ALND),
as is standard clinical practice, with clinical outcome data
availablewereselected.SLNsandALNswereselectedbasedon
theirdesignationassentineloraxillarybytheoperativereport;
the majority of SLNs are ALNs based on their location within
the breast at time of surgery. ALNs referred to in this study are
all ALNs not designated as SLNs. For this reason, reference in
this paper to ALNs and nonsentinel lymph nodes are
synonymous. In surgical cases involving multiple SLNs and
ALNs,oneSLN(SLNseries1)andoneALN(ALNseries1)were
arbitrarily selected by the Department of Pathology staff and
represent the training set(n¼29).The Pathology staff member
was blinded to the study design. As no randomization
technique was employed, the training set selection process
was by deﬁnition arbitrary rather than random. To test
reliability and variance of immune proﬁle, eight ALNs were
selected from a single patient. For purposes of validating the
training set, ﬁrst, a second SLN and ALN were randomly
selected (using the random selection function ‘‘sample’’ in R)
for each individual within the training set; these represent
training set SLN series 2 (n ¼ 18; 11 of 29 patients had only a
single SLN removed, which was included in SLN series 1), and
training set ALN series 2 (n¼27; an additional ALN could not
be retrieved for two of the original 29 patients). Second, a
singleALNwasrandomlyselectedforallindividualswithinthe
test set (n¼48). SLNs and ALNs from patients within training
set SLN series 2, training set ALN series 2, and the test set were
randomly selected using the sample function in R [21]. As
performed in prior studies to provide an average immune
proﬁle, ten control nodes—a single mesenteric node per
control individual—were similarly examined from patients
withbenigndiseasewithoutahistoryofmalignancyorimmune
disorder [22–24]. All samples were collected from Stanford
Department of Pathology Specimen Bank as coded specimens
undera protocol approved bythe Stanford University Medical
Center Institutional Review Board.
All participants were untreated and without a history of
cancer or immune disorder prior to breast cancer diagnosis
and SLN biopsy. Following surgical management, patients
received adjuvant therapy as determined by their medical and
radiation oncologists. The duration of disease-free survival
(DFS) was the time between initial diagnosis and ﬁrst
recurrence. All patients received SLN and ALN removal in
conjunction with removal of primary tumor within 44 d of
initial diagnosis. Initial diagnosis was performed by needle
aspiration or core biopsy in the majority of cases. Final
diagnosis was conﬁrmed from the pathologic evaluation of the
primary tumor from the lumpectomy specimen. The average
difference between time of diagnosis and surgery was 12.3 d.
Wechosetousetimeofdiagnosisratherthantimeofsurgeryto
determine clinical outcome, as we were measuring the
relationship between tumor and immune composition of local
nodes versus the inﬂuence of surgery on outcome. All
recurrences were based on documentation of local or systemic
disease during a follow-up period of 5 y, after which data were
censored. We recorded and veriﬁed patient, tumor, and lymph
node characteristics [25].
Immunostaining. Tissue sections, 3 lm thick, were cut from
formalin-ﬁxed, parafﬁn-embedded nodes. HES and IHC were
performed after antigen retrieval using Biogenex Genomx
i1000 (San Ramon, California, United States). Antibodies
included anti-CD4 (1/20, Novacastro; Vector Laboratories,
Burlingame, California, United States), anti-CD8 (1/25; Dako,
Glostrup,Denmark),anti-CD1a(1/100,Dako),anti-AE1/AE3(1/
25, Biogenex), and, as secondary antibody, EnVision dextran
kit (1/5, Dako). Optimal concentrations were determined, and
tested in sample node sections. Double staining using 3939
diaminobenzidene, VIP (Vector Laboratories), and a light
counterstain with Mayer’s hematoxylin (Innogenex) was
performed for lymphocyte populations of interest, with
colocalizationoftumorcells.Isotype-matchedantibodieswere
used as negative controls. All slides for the respective antibody
were stained in the same run.
Presence of metastasis was veriﬁed by HES and IHC on four
sections per node by two blinded investigators trained in
breast cancer pathology. Area of node occupied by each
immune cell type and by tumor was determined through
computerized image acquisition and analysis software (BLISS;
Bacus Laboratories, Lombard, Illinois, United States). Prior
image analyses determine cell count and area from an average
of ﬁve to 20 high-power ﬁelds [10,14,15,20,26]. Using BLISS we
acquired 160–4,130 sequential images at 2003 of the entire
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Lymph Node Immune Profile in Breast Cancerlymph node section, which were sequenced together by
Metamorph Imaging System (Universal Imaging, Sunnyvale,
California, United States). Objectives were calibrated to
transform image pixels to microns. Control nodes were
examined to standardize thresholds of each stain for cell of
interest. Using an automated Metamorph script, standardized
thresholds were applied with Metamorph log set to record
areasoccupiedbycellofinterest,tumor,andofentirenodefor
all samples, thus minimizing any potential operator bias.
Statistical analysis. Univariate and multivariate analyses
including logistic regression tested predictive capacity of
patient characteristics. Immune proﬁles of patients with and
without nodal metastasis, and with and without disease
recurrence, were compared by Wilcoxon rank sum test. F-test
for immune proﬁle equality of variance analysis was used to
determinevariancebetweennodesfromasinglepatientversus
nodes from different patients with similar characteristics [21].
Variance was also calculated for pairs of ALNs with similar
tumor status (either both tumor-free, or both tumor-involved)
from the same patient, versus variance for pairs of ALNs with
discordant tumor status (one tumor-free and one tumor-
involved)fromthesamepatient.ALNseries1immuneproﬁle’s
sensitivity and speciﬁcity in predicting disease recurrence
were determined from receiver-operating-characteristic
(ROC) curves based on the ALN immune proﬁle of patients
with versus without disease recurrence from the training set.
ALN series 1 immune proﬁle thresholds were applied to SLN
series 2, ALN series 2 and the test set with statistical
comparison by X
2 test. We constructed Kaplan-Meier (KM)
life-table curves for DFS, with permuted log-rank test
comparisons, as the sample size was limited. The training set
was stratiﬁed for KM curves by ALN series 1 and 2 immune
proﬁles, established from ROC curves applied to ALN series 1,
to test prediction of DFS. Nodal thresholds from the training
set ALN series 1 were also applied to the test set in KM curves
compared by permuted log-rank tests. For analyses involving
ALNs from all participants, the only available ALN from the
test set was selected. However, as the learning set had two
possible ALNs (series 1 and series 2), the sample function in R
was used to randomly select one of the two ALNs from the
learning set by random number generation. Finally, immune
proﬁle and clinicopathologic characteristics signiﬁcant by
univariate analyses among all 77 patients, those with T1
tumors, and/or those with T2 tumors were entered into a Cox
proportional hazards model. Two-sided p , 0.05 was consid-
eredastatisticallysigniﬁcantdifference.ForanalysesweusedR
statistical package [21,27,28].
Results
Patient, Primary Tumor, and Lymph Node Characteristics
Characteristics of the training set (29 patients) are shown in
Table 1. Of 29 SLN metastases in SLN series 1, all were tumor-
involved, ﬁve contained isolated tumor cells, 11 contained
micrometastases, and 13 contained macrometastases. Of 18
SLNs in series 2, nine were tumor-involved, three contained
micrometastases, and six contained macrometastases; 16
individuals had positive ALNDs. Of 29 arbitrarily selected
series 1 ALNs, nine were found to be tumor-involved, with
seven of the 20 tumor-free ALNs selected from patients with
positive ALNDs (ALNs other than the one selected for series 1
were found to be tumor-involved) (Figure S1). Of 27 randomly
selected series 2 ALNs, seven were tumor-involved (Figure S2).
Recurrent disease developed in 11 of 29 patients with 5 y of
follow-up; two of 11 recurrences (18%) occurred at a distant
site, and ten of 11 developed locoregional relapse (91%), with
one patient at time of relapse found to have both local and
distant disease.
Test set (48 patients) clinicopathologic characteristics are
shown in Table 1. All patients had a tumor-involved SLN
biopsy,withfourcontainingisolatedtumorcells,24containing
micrometastases, and 20 containing SLN macrometastases.
Recurrent disease developed in 22 (45.8%) of 48 patients
duringfollow-up of 5 y;14of 22occurred at distantsites, seven
developed locoregional relapse, and one recurred both at a
distant site and locally. ALNs selected from eight (36.3%) of 22
patients with disease recurrence were tumor-involved (Figure
S3). Of the 26 ALNs selected from patients without recurrent
disease, nine (34.6%) were tumor-involved.
Among all patients from both training set and test set (n ¼
77), only tumor size signiﬁcantly correlated with disease
recurrence (p ¼ 0.015). Among patients with only T1 tumors
(n¼41),percenttumorinvolvementintheSLNcorrelatedwith
disease recurrence more closely than all other clinicopatho-
logic characteristics, (p¼0.057). Likewise, among patients with
only T2 tumors (n¼33), size of SLN metastasis correlated with
disease recurrence more closely than all other clinicopatho-
logic characteristics (p¼0.041).
Alterations in Immune Profile of Tumor-Draining Lymph Nodes
To determine whether tumor-draining lymph nodes from
patientswithbreastcanceraredifferentimmunologicallythan
lymph nodes from control individuals, we initially analyzed
one SLN and one ALN from each of 29 breast cancer patients
(training set, Table 1) by IHC for CD4 T cell, CD8 T cell, and
CD1a dendritic cell populations (Figure 1). We found
signiﬁcant differences in CD4 and CD1a populations between
SLN, ALN,andcontrol nodes (Figure 1A). While control nodes
contained the highest percentages of CD4 and CD8 T cells,
ALNs contained the highest percentage of CD1a cells (Figure
1A). The magnitude of CD4 population decrease from control
nodestoSLNswasover10-foldgreaterthantheCD8decreases
between these nodes. SLNs also displayed signiﬁcant decreases
in CD1a cells. Interestingly, CD1a cells were elevated in ALNs
even above controls. To determine if tumor invasion is a
prerequisite for alterations in immune proﬁle, training set
SLNs and ALNs were grouped together as tumor-free or
tumor-involved, which revealed dramatic differences in CD4
and CD1a populations and CD4:CD8 ratio based on tumor
status (Table 2). Furthermore, training set ALNs (Figure S1)
were stratiﬁed as tumor-involved (n ¼ 9), tumor-free from an
individual with positive ALND (n¼7), or tumor-free from an
individual with negative ALND (n ¼ 13). CD4 and CD1a cells
were signiﬁcantly decreased in tumor-involved ALNs (Figure
1E). Intriguingly, CD4 populations were decreased even in
tumor-freeALNs(Figure1E),suggestingthatthesechangesare
not merely a reﬂection of tumor invasion. In contrast, tumor-
free ALNs showed signiﬁcant increases in CD1a cells, which is
more dramatic in those from individuals with a positive ALND
(Figure 1E). Analysis of percent of node involved by tumor and
magnitude of CD4, CD8, or CD1a changes did not show a
statistically signiﬁcant relationship. These observations argue
against a simple linear relationship between immune alter-
ationsandtumorinvasion,butsuggestthatdynamicchangesin
theimmuneproﬁlewithintumor-draininglymphnodesmayin
fact precede tumor invasion.
Relationship between SLN Immune Profile and Axillary
Metastasis or DFS
We investigated whether a relationship exists between SLN
immune proﬁle and ALN metastasis or DFS. While SLN CD4
PLoS Medicine | www.plosmedicine.org September 2005 | Volume 2 | Issue 9 | e284 0908
Lymph Node Immune Profile in Breast CancerFigure 1. Lymph Node Profile of Sentinel and Axillary Lymph Nodes
Mean and standard error of CD4 and CD8 T cell, CD1a dendritic cell populations as percent of lymph node, and CD4:CD8 cell ratio are shown for (A) SLN
(n¼29), ALN (n¼29), and control lymph nodes (n¼10); (E) tumor-involved ALNs (n¼9), tumor-free ALNs (n¼7) from patients with a positive ALND,
tumor-free ALNs from patients with a negative ALND (n ¼ 13), and controls (n ¼ 10); (I) SLNs and ALNs stratified by disease recurrence during 5 y of
follow-up (11 of 29 with recurrent disease); (L) tumor-involved ALNs stratified by disease recurrence (n ¼ 9); (M) tumor-free ALNs from patients with a
positive ALND stratified by disease recurrence (n¼7); and (N) tumor-free ALNs from patients with a negative ALND stratified by disease recurrence (n¼
13). Representative 2003images of lymphocyte population (brown staining) and infiltrating tumor (purple staining) by IHC, including CD8 T cells in (B)
SLNs, (C) ALNs, and (D) controls; (F) CD4 T cells in tumor-involved ALNs, (G) tumor-free ALNs from patients with a positive ALND, (H) tumor-free ALNs
from patients with a negative ALND; and (J) CD1a dendritic cells in ALNs from patients disease-free versus (K) patients who developed recurrence.
DOI: 10.1371/journal.pmed.0020284.g001
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Lymph Node Immune Profile in Breast Cancerpopulations and CD4:CD8 ratio demonstrated a trend toward
anassociationwithaxillarymetastasis(Table3),CD8andCD1a
populations showed no such relationship. When SLN immune
proﬁlewasanalyzedforDFS,CD8populationsshowedatrend;
however, all other cell populations showed no statistically
signiﬁcant relationship with survival (Figure 1I; Table 3).
ALN Immune Profile and Disease-Free Survival
In contrast to SLNs, which exhibited similar immune proﬁle
changes in all 29 training set individuals, ALN CD4 and CD1a
populations showed signiﬁcant differences between patients
with recurrence versus those disease-free at 5 y (p , 0.001)
(Figure1Iand1K;Table4).Furthermore,associationsbetween
disease recurrence and changes in ALN CD4 and CD1a
populations were independent of nodal metastasis or ALND
status (Figure 1L–1N). Among patients with disease recur-
rence, degree of decrease in CD4 T cell and CD1a dendritic
cell populations was similar (greater than 4-fold) among
tumor-involved ALNs and tumor-free ALNs from either
positive or negative ALNDs. These ﬁndings support a direct
relationship between ALN immune proﬁle and disease-free
survival—even within these arbitrarily selected ALNs (series
1), regardless of nodal and locoregional metastasis status.
To expand on the applicability of these ﬁndings, we
randomly selected a second ALN from 27 of the 29
individuals in the training set (series 2, Figure S2). Immune
proﬁle thresholds determined from ROC curve analysis for
maximal predictive accuracy among the training set ALN
series 1 were applied to these additional 27 ALNs. Strat-
iﬁcation of the training set into favorable and unfavorable
prognostic groups for CD4 and CD1a populations was highly
Table 2. Immune Profile and Nodal Status
Cell Population Tumor-Free
Lymph Node,
% of Lymph Node
(Mean 6 SE, n ¼ 20)
Tumor-Involved
Lymph Node,
% of Lymph Node
(Mean 6 SE, n ¼ 38)
Control Lymph Node,
a
% of Lymph Node
(Mean 6 SE, n ¼ 10)
Wilcoxon Rank
Sum Test
b p-Value
CD4 17.85 6 2.19 2.11 6 0.35 31.93 6 4.76 ,0.001
CD8 7.93 6 0.99 7.52 6 0.71 13.12 6 1.71 0.890
CD1a 3.59 6 0.56 0.26 6 0.06 1.17 6 0.32 ,0.001
CD4:CD8 Ratio 2.47 6 0.28 0.34 6 0.08 2.33 6 0.16 ,0.001
Training set analysis (29 series 1 SLNs, 29 series 1 ALNs, total lymph nodes n ¼ 58).
aTumor-free control lymph nodes selected from ten patients without cancer or immunodeficiency.
bWilcoxon rank sum test for tumor-free lymph node immune profile versus tumor-involved lymph node immune profile.
SE, standard error.
DOI: 10.1371/journal.pmed.0020284.t002
Table 3. SLN Immune Profile and Clinical Outcome
Cell
Population
Axillary Metastases DFS
% of SLN of
Patients without
Axillary Metastases
(Mean 6 SE, n ¼ 13)
% of SLN of
Patients with
Axillary Metastases
(Mean 6 SE, n ¼ 16)
Wilcoxon Rank
Sum Test
p-Value
% of SLN of
Patients Disease-
Free at 5 y
(Mean 6 SE, n ¼ 18)
% of SLN of Patients
with Recurrent
Disease at 5 y
(Mean 6 SE, n ¼ 11)
Wilcoxon Rank
Sum Test
p-Value
CD4 1.59 6 0.38 1.00 6 0.21 0.120 1.22 6 0.30 1.34 6 0.27 0.220
CD8 6.30 6 0.76 7.40 6 1.29 0.999 7.86 6 1.08 5.36 6 0.92 0.076
CD1a 0.22 6 0.07 0.28 6 0.12 0.693 0.18 6 0.04 0.38 6 0.16 0.234
CD4/CD8 Ratio 0.28 6 0.07 0.16 6 0.11 0.101 1.22 6 0.30 1.34 6 0.27 0.220
SE, standard error.
DOI: 10.1371/journal.pmed.0020284.t003
Figure 2. Disease-free Survival Analysis of Women with Breast Cancer According to Immune profile Characteristics, Learning Set ALN Series 2, and Test
Set
KM curves are shown for (A) median DFS applied to the learning set ALN series 2 (n¼27) and test set (n¼48) according to size of CD4 T cell and CD1a
dendritic cell populations within learning set ALN series 2 (second, randomly selected ALN per individual); (B) DFS stratified by size of CD4 T cell and
CD1a dendritic cell populations within test set ALNs; and (C) DFS applied to the learning set (n¼29) and test set (n¼48) according to size of ALN CD4 T
cell and ALN CD1a dendritic cell populations. Thresholds for ALN CD4 T cell and ALN CD1a dendritic cell populations were determined by ROC curves as
applied to the learning set (ALN series 1). Median duration of DFS are indicated; – indicates a median DFS greater than follow-up period, 5 y. Of 29
individuals in learning set ALN series 1, 11 had recurrent disease, and of 27 individuals in learning set ALN series 2, 11 had recurrent disease. Of 48
individuals in the test set of ALNs, 22 had recurrent disease. For ALN selection from the learning set (C), a single ALN was randomly selected from series
1 or series 2 per individual. Adjusted p-values were determined by the permuted log-rank statistic for comparison of DFS between groups.
DOI: 10.1371/journal.pmed.0020284.g002
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Lymph Node Immune Profile in Breast Cancersigniﬁcant as displayed in KM curves of DFS (p¼0.005 and p¼
0.007, respectively) (Figure 2A; Table 4).
Additional comparison of immune proﬁle and patient
characteristics within the training set demonstrated ALN
CD4 T cell and CD1a dendritic cell populations had superior
predictive capacity of DFS (p ¼ 0.001 for both) compared to
the degree of tumor involvement in SLNs and ALNs or to
primary tumor size, by ROC curve analyses (p ¼ 0.039, p ¼
0.102, and p ¼ 0.072) (Figure S4). KM curves indicated
signiﬁcant stratiﬁcation of DFS by percent of tumor involve-
ment in SLN series 1, tumor stage, and ALN CD1a and CD4
populations (Figure 3) (p¼0.043, p¼0.096, p¼0.001, and p¼
0.025). Patient stratiﬁcation by both ALN CD4 T cell
population and tumor stage predicted DFS equally as well
as, if not better than, the most statistically signiﬁcant
clinicopathologic characteristics (tumor stage and percent
of tumor involvement in the SLN) (Figure 3C).
Intra-Individual Versus Inter-Individual Variance in Lymph
Node Immune Profile
To more fully address the issue of internodal variance in
immune proﬁle from a single individual, we analyzed the
immune proﬁles of eight randomly selected ALNs from a
single patient. The variance of these nodes was compared to
the variance of nodes from different individuals with similar
patient characteristics, including similar recurrent disease
state (n ¼ 66). Equality of variance testing illustrated intra-
individual homogeneity between nodes relative to inter-
individual nodal variance for CD1a, CD4, and CD8 (F[65,7]-
statistics of 24.65, 26.89, and 10.23; corresponding signiﬁ-
cances p , 0.001, p , 0.001, and p ¼ 0.002, respectively).
Validation of the Predictive Capacity of ALN Immune
Profile
To further validate the predictive capacity of ALN immune
proﬁle for DFS in breast cancer, we analyzed one randomly
selected ALN from an additional 48 patients (test set, Table
1), 22 of which developed recurrent disease in 5 y. Thresholds
determined by ROC curves from the training set series 1 were
applied to the test set data, which demonstrated highly
signiﬁcant stratiﬁcation of favorable and unfavorable risk of
recurrent disease (KM curves of DFS and permuted log-rank
tests signiﬁcant with p , 0.001 for both CD4 and CD1a
populations; Figure 2B). Final comparison of the predictive
strength of ALN immune proﬁle relative to the most
predictive clinicopathologic characteristics was performed
for all patients with recurrence status available (single ALN
selected randomly from learning set series 1 or series 2, n ¼
27; and ALN test set, n¼48; total ALNs n¼77; Figure 2C). Of
77 patients analyzed, 33 developed recurrent disease during
the follow-up period. Among all patients from both training
set and test set, only tumor size signiﬁcantly correlated with
disease recurrence (p¼0.015). KM curves of DFS stratiﬁed by
ALN CD4 population and ALN CD1a population demon-
strate superior risk stratiﬁcation for recurrence by immune
proﬁling compared to tumor size (p , 0.001, p , 0.001, and p
¼ 0.004, respectively; Figures 2C and 4A).
Table 4. ALN Immune Profile and DFS
Cell
Population
Learning Set, ALN Series 1
Immune Profile (n¼ 29)
a
Learning Set, ALN Series 2
Immune Profile (n¼ 27)
b
Test Set, ALN
Immune Profile (n¼ 48)
c
Immune Profile
of Patients
Disease-Free,
%o f
Lymph Node
(Mean 6 SE)
Immune Profile
of Patients
with Recurrent
Disease,
%o f
Lymph Node
(Mean 6 SE)
Wilcoxon
Rank
Sum Test
p-Value
Immune Profile
of Patients
Disease-Free,
%o f
Lymph Node
(Mean 6 SE)
Immune Profile
of Patients
with Recurrent
Disease, %
of Lymph Node
(Mean 6 SE)
Wilcoxon
Rank
Sum Test
p-Value
Immune Profile
of Patients
Disease-Free,
%o f
Lymph Node
(Mean 6 SE)
Immune Profile
of Patients
with Recurrent
Disease, %
of Lymph Node
(Mean 6 SE)
Wilcoxon
Rank
Sum Test
p-Value
CD4 18.8 6 2.35 5.62 6 0.63 ,0.001 18.17 6 3.48 10.20 6 3.77 0.026 26.57 6 2.31 4.38 6 1.42 ,0.001
CD8 8.88 6 0.96 7.66 6 1.53 0.493 9.57 6 1.17 11.07 6 3.22 0.512 17.88 6 1.04 5.79 6 0.89 ,0.001
CD1a 3.83 6 0.59 0.47 6 0.11 ,0.001 2.42 6 0.55 0.60 6 0.22 0.015 3.02 6 0.37 0.41 6 0.13 ,0.001
aALN Series 1, 11 of 29 patients with recurrent disease with 5 y of follow-up.
bALN Series 2, 11 of 27 patients with recurrent disease with 5 y of follow-up.
cTest Set, 22 of 48 individuals with recurrent disease with 5 y of follow-up.
SE, standard error.
DOI: 10.1371/journal.pmed.0020284.t004
Figure 3. DFS Analysis of Women with Breast Cancer According to Tumor and Immune profile Characteristics, Learning Set ALN Series 1
KM curves are shown for (A) median DFS applied to the learning set, n¼29, according to percent of SLN occupied by infiltrating tumor (determined by
IHC), and stratified by tumor stage; (B) DFS according to size of CD4 T cell and CD1a dendritic cell populations within learning set ALN series 1 (first,
arbitrarily selected ALN per individual); and (C) DFS stratified both by percent of SLN infiltrated by tumor and tumor stage, and by both axillary node
CD4 T cell population and by tumor stage. A comparison of survival by all subgroups and a separate comparison of stratified T2 alone are included (* in
[C]). Thresholds for percent tumor infiltration within SLN, ALN CD4 T cell, and ALN CD1a dendritic cell populations were determined by ROC curves as
applied to the learning set (SLN and ALN series 1). Median duration of DFS are indicated; – indicates a median DFS greater than follow-up period, 5 y. Of
29 individuals, 11 had recurrent disease. Adjusted p-values were determined by the permuted log-rank statistic for comparison of disease-free survival
between groups.
TI, tumor infiltration.
DOI: 10.1371/journal.pmed.0020284.g003
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Lymph Node Immune Profile in Breast CancerStrength of ALN Immune Profile as Predictors of DFS in
Early Stage Patients (T1 and T2 Tumors)
The predictive value of ALN immune proﬁle was partic-
ularly striking in early stage breast cancer patients (with T1
and T2 tumors) (Figure 4). Among the learning set, patients
with T2 tumors and ALN CD4 population less than 7.0% had
a median duration to recurrence of 9 mo and ﬁve-year DFS
rate of 0%, versus a median DFS greater than follow-up
period of 5 y and DFS rate of 88% for those with T2 tumors
and ALN CD4 population of 7.0% or above (p¼0.01) (Figure
4C). By immune proﬁling of the entire study population (n ¼
77), median DFS for the unfavorable CD4 and CD1a proﬁles
among 33 patients with T2 tumors were both 24 mo with DFS
rates of 13% and 0.0%, respectively. In contrast, favorable
ALN CD4 and CD1a proﬁles portended DFS rate of 94% and
86%, respectively. DFS according to CD4 and CD1a immune
proﬁles was superior to all other clinicopathologic character-
istics, the most predictive characteristic being size of SLN
metastasis (permuted log-rank test, ALN CD4, p , 0.001; ALN
CD1a, p , 0.001; and size of SLN metastasis, p ¼ 0.03).
Furthermore, ALN immune proﬁles of CD4 or CD1a cells
were signiﬁcantly superior to prognostic capacity by amount
of local metastatic tumor burden (number of tumor-involved
ALNs, p . 0.05) among patients with T2 tumors.
For patients with T1 tumors, we similarly determined the
best current clinicopathologic predictor of disease recur-
rence in 41 patients with T1 tumors among our study
population. This characteristic, percent of tumor involve-
ment within the SLN, was an inferior predictor to immune
proﬁling by ALN CD4 and CD1a (permuted log-rank test,
percent tumor involvement in SLN, p¼0.049; CD4, p , 0.001;
and CD1a, p ¼ 0.001; Figure 4B). By ALN immune proﬁling
among patients with T1 tumors, median DFS for the
unfavorable CD4 and CD1a proﬁles were both 36 mo with
DFS rates of 20% and 29%, respectively. Favorable ALN
immune proﬁles portended a signiﬁcantly more favorable
DFS rate of 88% and 81% for CD4 and CD1a among patients
with T1 tumors. Thus, for patients with T1 tumors, DFS
according to CD4 and CD1a immune proﬁles was also
superior to current clinicopathologic characteristics, includ-
ing the number of tumor-involved ALNs (p . 0.05).
Relationships between Immune Profile and Metastasis in
SLN and ALN
To address potential mechanisms of immune changes in
breast cancer-draining lymph nodes, we further explored the
dependence of immune proﬁle changes on nodal tumor
metastasis in SLNs and ALNs. Immune proﬁle thresholds
determined from ROC curve analysis of training set series 1
lymph nodes (CD4 at 7%, CD1a at 0.6%) were applied to
SLNs from training set series 2 and ALNs from training set
series 2 and the test set. While all of the series 1 SLNs were
tumor-involved, only 50% of the series 2 SLNs were involved,
making such an analysis possible for both SLN and ALN.
Lymph nodes were segregated based on immune proﬁle
changes and nodal metastasis (Table 5). Among the 18 SLNs,
all nine (100%) tumor-involved SLNs showed decreased
percentages of CD4 cells, and 77.8% showed decreased
percentages of CD1a cells. Conversely, 81.8% and 77.8% of
SLNs with relatively normal percentages of CD4 cells and
CD1a cells, respectively, were tumor-free. X
2 testing for CD4
and CD1a, with p-values of less than 0.001 and 0.017,
respectively, demonstrate the strength of relationship be-
tween tumor involvement and immune proﬁle in SLNs.
Importantly, ALN analysis of 75 nodes from training set
series 2 and the test set, 24 of which were tumor-involved, did
not demonstrate a similar effect of nodal tumor status on
nodal immune proﬁle (Table 5). Of the 24, 11 (46%) tumor-
involved ALNs exhibited preserved CD4 percentages, and 14
(58%) exhibited preserved CD1a percentages. Furthermore,
of 51 tumor-free ALNs, 21 (41%) and 23 (45%) exhibited
decreased percentages of CD4 or CD1a cells, respectively.
Hence, among these ALNs, no statistically signiﬁcant associ-
ation was found between decreased CD4 or CD1a populations
and nodal tumor involvement (p-values 0.298 and 0.784,
respectively). To address the dependence of ALN immune
proﬁle on nodal tumor status, we directly compared the
immune proﬁles of series 1 and series 2 ALNs from the same
patient. Of 27 paired ALNs, seven were discordant (one
tumor-involved and one tumor-free), allowing us to address
whether nodal metastasis is the dominant cause of ALN
immune proﬁle changes within individuals. Interestingly, the
variance between discordant ALN pairs from the same
patients was the same or even less than the variance between
concordant ALN pairs (both tumor-involved or both tumor-
free) (Table 6). This further supports the possibility that ALN
immune proﬁle change is driven by a separate process from
nodal metastasis.
Finally, the independent predictors of DFS are shown in
Table 7. The most signiﬁcant independent predictors were
percent of CD1a and CD4 cells in the ALN (hazards ratios of
0.42 and 0.93, respectively). Tumor size displayed a trend with
recurrence (although not signiﬁcant at p , 0.05), with a
hazards ratio of 1.18. Neither the percent of tumor within the
analyzed ALN, nor the size of tumor metastasis within the
SLN, were associated with DFS by Cox proportional hazards
modeling. These ﬁndings point to the intriguing possibility
that immune proﬁle changes and nodal metastasis may be
independent processes in ALN. This is in contrast to SLN, in
which immune proﬁle changes appear dependent on nodal
metastasis. Importantly, our data show that ALN immune
proﬁle—not SLN immune proﬁle (see Table 3) or ALN
metastasis (Table 8)—predicts DFS in breast cancer.
Figure 4. DFS Analysis of Women with Breast Cancer According to Tumor Stage, T1 and T2, and Immune Profile Characteristics, Learning and Test Sets
KM curves are shown for (A) median DFS applied to the learning set (n¼29) and test set (n¼48) according to tumor stage; (B) DFS stratified by size of
ALN CD4 T cell and ALN CD1a dendritic cell populations among individuals with T1 tumors; and (C) DFS stratified by size of ALN CD4 T cell and ALN
CD1a dendritic cell populations among individuals with T2 tumors. Thresholds for ALN CD4 T cell and ALN CD1a dendritic cell populations were
determined by receiver-operating-characteristic curves as applied to the learning set (ALN series 1). Median duration of DFS are indicated; – indicates a
median DFS greater than follow-up period, 5 y. Of 77 individuals, 33 had disease recurrence. Of 41 from individuals with T1 tumors, 15 had recurrent
disease. Of 33 individuals with T2 tumors, 15 had disease recurrence. For ALN selection from the learning set, a single ALN was randomly selected from
series 1 or series 2 per individual. Adjusted p-values were determined by the permuted log-rank statistic for comparison of DFS between groups.
DOI: 10.1371/journal.pmed.0020284.g004
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It is now widely accepted that the status of tumor-draining
lymph nodes signiﬁcantly predicts clinical outcome in breast
cancer. However, current clinical practice involves only
histological examination of such nodes for the presence or
absence of tumor, largely ignoring the immunological nature
of lymph nodes in cancer. As the systemic immune response is
clearly inﬂuenced by tumor progression, immune proﬁle
changes in early sites of immune system-cancer interactions,
i.e., tumor-draining nodes, may represent a sensitive indica-
tor of tumor metastasis [10,16,22]. More signiﬁcantly, the
nature of such immunological changes may provide addi-
tional biological and prognostic information. In this study, we
analyzed the lymph node immune proﬁles in 77 breast cancer
patients with tumor-involved SLNs, 42 of which had tumor-
positive ALNDs. Importantly, in 5 y of follow-up, 33 patients
had disease recurrence, allowing us to correlate nodal
immune proﬁle with clinical outcome. Four patients had
SLNs containing isolated tumor cells (0.2 mm or smaller)
detected by only IHC—these patients developed disease
recurrence, supporting the clinical signiﬁcance of IHC-only
positive SLNs [6,7,29]. As in other studies, mesenteric nodes
from patients with benign disease were used as comparisons,
since axillary nodes are rarely excised for nonmalignant
conditions [22–24]; immune proﬁle of control nodes paral-
leled literature standards [23,24]. Importantly, new computer-
based imaging techniques provided high-resolution image
acquisition of the entire nodal surface. We acquired a total of
160–4,130 images (2003 magniﬁcation) per nodal section,
while prior studies based their results on only 5–20 images
per section [10,14,15,20,26]. By such detailed, automated
analysis of SLNs and ALNs, we identiﬁed unique patterns in
the degree of CD4 helper T cell, CD8 cytotoxic T cell, and
CD1a dendritic cell decreases relative to each other and
controls.
An intriguing result from this study is that even tumor-free
ALNs exhibited changes in immune proﬁle, with suppression
of CD4 and CD8 T cells relative to controls. In contrast,
tumor-free ALNs exhibited higher dendritic cell populations
than controls, and this elevation was more prominent in
tumor-free ALNs from patients with positive ALNDs than
from patients with negative ALNDs. This demonstrates that
perturbations of the immune proﬁle in tumor-free ALNs are
dynamic and may occur before gross nodal metastasis. Our
ﬁndings extend prior studies in melanoma, lung, head and
neck, gastric, and breast cancer, which linked immune down-
regulation only to tumor invasion, and also show that the
relationship between increasing tumor invasion and changes
in immune proﬁle is not a simple linear one, as previously
suggested [18,30–33].
While prognostic factors, including lymph node metastasis,
tumor size, and histological grade, for breast cancer
recurrence and overall survival are well established, few
studies have thoroughly examined the inﬂuence of immune
Table 5. Sentinel and Axillary Lymph Node Immune Profile and Nodal Metastases
Lymph Node Group Cell Population
a Tumor-Free Lymph Node, n (%) Tumor-Involved Lymph Node, n (%) X
2 Test
b p-Value
SLN (n ¼ 18)
c CD4 ,0.001
,7% (n ¼ 7) 0 (0.0) 7 (100.0)
 7% (n ¼ 11) 9 (81.8) 2 (18.2)
CD1a 0.017
,0.6% (n ¼ 9) 2 (22.2) 7 (77.8)
 0.6% (n ¼ 9) 7 (77.8) 2 (22.2)
ALN (n ¼ 75)
d CD4 0.298
,7% (n ¼ 34) 21 (61.8) 13 (38.2)
 7% (n ¼ 41) 30 (73.2) 11 (26.8)
CD1a 0.784
,0.6% (n ¼ 33) 23 (69.7) 10 (30.3)
 0.6% (n ¼ 42) 28 (66.7) 14 (33.3)
aDown-regulated immune profile by CD4% or CD1a% nodal surface area thresholds determined from training set analysis.
bX
2 test for tumor-free lymph node immune profile CD4 and CD1a thresholds versus tumor-involved lymph node immune profile CD4 and CD1a thresholds.
cNine tumor-involved SLNs from training set series 2 (n ¼ 18).
dSeven tumor-involved ALNs from training set series 2 (n ¼ 27), and 17 tumor-involved from test set (n ¼ 48); total 24 of 75 axillary nodes are tumor-involved.
DOI: 10.1371/journal.pmed.0020284.t005
Table 6. Intra-Individual ALN Immune Profile Variance
ALN Set CD1a
a CD4
a CD8
a CD4:CD8
a
TFLN versus TILN
b 0.93 0.14 1.02 0.09
TFLN versus TFLN
TILN versus TILN
c 1.22 2.97 2.14 0.21
aInternodal, intra-individual variance between ALN pairs of discordant tumor-involvement status and identical tumor-involvement status (n ¼ 27).
bDiscordant tumor status among ALN series 1 and series 2 (n ¼ 7).
cIdentical tumor status among ALN series 1 and series 2 (n ¼ 20).
TFLN, tumor-free lymph node; TILN, tumor-involved lymph node.
DOI: 10.1371/journal.pmed.0020284.t006
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ﬁndings represent the ﬁrst demonstration of the clinical
signiﬁcance of T helper and dendritic proﬁles within tumor-
draining nodes of breast cancer patients in predicting DFS. A
recent study identiﬁed a direct relationship with SLN
dendritic cell density and DFS in melanoma [34]. However,
we found that the immune proﬁle of SLNs does not display
the predictive strength of ALN proﬁling, but rather reﬂects
largely the metastatic status of the SLN (either tumor-
involved or tumor-free). In contrast, the ALN immune proﬁle
appears much less inﬂuenced by the presence of intranodal
metastatic tumor cells. We speculate that as the direct (tumor
inﬁltration) and indirect (altered cytokine proﬁle) effects of
cancer progression alter the nodal environment, the pre-
dictive capacity of the SLN immune proﬁle becomes
diminished, and the inﬂuence of inﬁltrating tumor is
augmented. This is analogous to observations in melanoma,
in which proximity to primary tumor is the dominant
determinant of immune proﬁle [30,35,36]. By proﬁling ALNs,
we observed a predictive accuracy of recurrence by dendritic
and T cell populations that is superior even to the predictive
accuracy of tumor involvement within the identical node.
Furthermore, ALN immune proﬁle predicted recurrence
independent of presence or absence of metastasis on ALND.
Therefore, a single axillary (nonsentinel) node, selected
regardless of tumor involvement within the node or the
overall status of all other nodes from the patient’s ALND,
contains a unique immune proﬁle of potential prognostic
value.
In summary, our ﬁndings suggest that changes in the
immune proﬁle of breast cancer-draining lymph nodes
appear to accompany, and may precede, tumor invasion.
Perturbation of the SLN immune proﬁle, while highly
correlated with the presence of inﬁltrating metastases, does
not add further predictive value in patient prognosis. In
contrast, our data show that ALN immune proﬁle does
predict DFS much better than it does ALN nodal metastasis.
These ﬁndings raise the intriguing possibility that two
independent processes may be responsible for the immune
changes in sentinel versus axillary lymph nodes. The
prognostic value of ALNs is highlighted by the capacity of
immune proﬁling of a single, randomly selected ALN to
stratify risk of recurrence among early stage breast cancer.
Immune proﬁling of ALN CD4 T cells and CD1a dendritic
Table 8. ALN Immune Profile, Tumor Stage, and DFS
Cell
Population
All ALNs (n ¼ 77)
a All ALNs, T1 Tumors (n ¼ 41)
b All ALNs, T2 Tumors (n ¼ 33)
c
Immune Profile
of Patients
Disease-free,
%o f
Lymph Node
(Mean 6 SE)
Immune Profile
of Patients
with Recurrent
Disease,
%o f
Lymph Node
(Mean 6 SE)
Wilcoxon Rank
Sum Test
p-Value
Immune Profile
of Patients
Disease-free,
%o f
Lymph Node
(Mean6 SE)
Immune Profile
of Patients
with Recurrent
Disease, %
of Lymph Node
(Mean6 SE)
Wilcoxon Rank
Sum Test
p-Value
Immune Profile
of Patients
Disease-free,
%o f
Lymph Node
(Mean 6 SE)
Immune Profile
of Patients
with Recurrent
Disease, %
of Lymph Node
(Mean 6 SE)
Wilcoxon Rank
Sum Test
p-Value
CD4 23.40 6 1.75 4.80 6 0.96 ,0.001 23.67 6 2.43 6.55 6 1.97 ,0.001 23.01 6 2.52 3.15 6 0.57 ,0.001
CD8 14.20 6 0.99 6.42 6 0.79 ,0.001 14.35 6 1.44 8.69 6 1.41 0.041 13.97 6 1.27 4.40 6 0.61 ,0.001
CD1a 3.35 6 0.33 0.43 6 0.09 ,0.001 3.07 6 0.42 0.60 6 0.18 ,0.001 3.77 6 0.51 0.28 6 0.08 ,0.001
Infiltrating
tumor cells
d 1.90 6 0.85 1.83 6 0.58 0.226 2.37 6 1.40 1.30 6 0.70 0.355 1.21 6 0.75 2.27 6 1.00 0.556
aAll individuals, 77 axillary lymph nodes from the training set (n ¼ 29) and ALN test set (n ¼ 48). Of 77 patients, 33 were selected from patients with recurrent disease with 5 y of follow-up.
bAll ALNs selected from patients with T1 tumors, 15 of 41 patients with recurrent disease with 5 y of follow-up.
cAll ALNs selected from patients with T2 tumors, 15 of 33 patients with recurrent disease with 5 y of follow-up.
dPercent of ALN occupied by infiltrating breast tumor cells.
A single ALN from each individual within the learning set was randomly selected from ALN series 1 or ALN series 2.
SE, standard error.
DOI: 10.1371/journal.pmed.0020284.t008
Table 7. Cox Proportional Hazards Model for DFS
Variable Hazard Ratio 95% Confidence Interval p-Value
Lower Upper
ALN % CD1a 0.42 0.239 0.738 0.003
ALN % CD4 0.93 0.877 0.990 0.023
Tumor size 1.18 0.989 1.407 0.065
ALN % tumor involvement 0.01 0.001 3.617 0.581
Size of SLN metastasis 1.1 0.566 2.131 0.783
77 patients, 33 with recurrent disease during follow-up of 5 y.
DOI: 10.1371/journal.pmed.0020284.t007
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population at high risk of recurrence signiﬁcantly better than
all available clinicopathologic patient characteristics. The
additional prognostic signiﬁcance of the immune proﬁle
among this subset of breast tumors is not possible by other
patient, tumor, or lymph node characteristics. These obser-
vations warrant a larger, prospective conﬁrmatory study. Our
ﬁndings support that a subset of patients may be at higher
risk of recurrence due to the extent of immune proﬁle
changes, and may therefore justify consideration of more
aggressive therapy. Finally, our ﬁndings offer possible
mechanisms underlying breast cancer’s poor immunogenic-
ity, due to either deﬁcient co-stimulation secondary to low
helper T cell populations, or inability to activate T cells as a
result of down-regulation of antigen-presenting dendritic
cells. Strategies to augment T cell and dendritic cell
populations and function within tumor-draining nodes may
increase the potential for an effective immune response and
thus improve clinical outcome among breast cancer patients.
Supporting Information
Figure S1. ALN Status, Learning Set Series 1
ALND was positive in 16 of 29 individuals. Tumor involvement was
determined for a single ALN per individual (learning set ALN series
1) (n¼29), and nine ALNs contained tumor inﬁltration. Of 20 tumor-
free ALNs, seven were selected from patients with a positive ALND
and 13 from patients with a negative ALND.
Found at DOI: 10.1371/journal.pmed.0020284.sg001 (64 KB TIF).
Figure S2. ALN Status, Learning Set Series 2
ALND was positive in 16 of 29 individuals. Tumor involvement was
determined for a single ALN per individual (learning set ALN series
2) (n ¼ 27), and seven ALNs contained tumor inﬁltration. Of 20
tumor-free ALNs, eight were selected from patients with a positive
ALND and 12 from patients with a negative ALND.
Found at DOI: 10.1371/journal.pmed.0020284.sg002 (64 KB TIF).
Figure S3. ALN Status, Test Set
ALND was positive in 31 of 48 individuals. Tumor involvement was
determined for a single ALN per individual (test set) (n¼ 48), and 17
ALNs contained tumor inﬁltration. Of 31 tumor-free ALNs, 14 were
selected from patients with a positive ALND and 17 from patients
with a negative ALND.
Found at DOI: 10.1371/journal.pmed.0020284.sg003 (64 KB TIF).
Figure S4. Predictive Strength of Patient and Immune Proﬁle
Characteristics, Learning Set
(A) ROC curve calculating the sensitivity and speciﬁcity of lymph
node CD4 T cell, CD1a dendritic cell, and ratio of CD4:CD8 T cell
populations in detecting nodal metastases from the learning set (SLN,
n ¼ 29; ALN series 1, n ¼ 29).
(B) ROC curve calculating the sensitivity and speciﬁcity of, ﬁrst,
primary tumor size and percent of lymph node occupied by
inﬁltrating tumor, and second, ALN series 1 CD4 T cell, CD1a
dendritic cell, and ratio of CD4:CD8 T cell populations in predicting
DFS. ALN series 1 represent the ﬁrst, arbitrarily selected ALN per
individual in the learning set. Greater area under the curve indicates
greater predictive strength. Adjusted p-values were determined by
ROC curve testing for comparison of variable’s predictive capacity.
Found at DOI: 10.1371/journal.pmed.0020284.sg004 (59 KB TIF).
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Patient Summary
Background In its earliest stage, breast cancer is confined to the breast
itself, but subsequently many cancers spread to other tissues. This often
happens through the lymphatic system, a set of canals similar to blood
vessels that transport lymph fluid. Lymph nodes are filters along the
lymphatic system. The lymph fluid draining away from the breast area is
mostly filtered in a set of lymph nodes in the armpit, the so-called axillary
lymph nodes. To find out whether a breast cancer has started to spread,
doctors routinely check the lymph nodes for breast cancer cells that have
escaped from the tumor in the breast. This used to involve surgery to
remove many or all of the approximately 30 axillary lymph nodes.
Because the surgery can lead to side effects like chronic pain and
swelling, doctors have started more recently to first remove the
‘‘sentinel’’ lymph node—the first filter through which the lymph from
the tumor tissue drains. In most cases, additional nodes are removed
only if this first one is found to contain cancer cells.
Why Was This Study Done? We know that our immune system can
recognize and fight cancer cells. Cancer develops only once the immune
system has been compromised, and the actual state of the immune
system might tell us something about how easy and quickly the cancer
will grow and spread. Because the lymph fluid contains many immune
system cells, the researchers thought that (besides looking for cancer
cells) it might be worth checking the lymph nodes that are closest to the
tumor for immune system activity.
What Did the Researchers Do and Find? They counted the numbers of
different immune system cells in lymph nodes from 77 breast cancer
patients. All of the patients had tumor cells in their sentinel lymph nodes,
and in 42 patients tumor cells were also found in other axillary lymph
nodes. For all patients, the researchers knew whether their cancers came
back within five years of removing the lymph nodes. They found that the
pattern of immune cells in the sentinel lymph nodes correlated with the
presence of cancer cells. In the axillary lymph nodes, however, the
decrease in two types of immune cells was correlated with disease-free
survival regardless of the presence or absence of tumor cells in these
nodes.
What Does This Mean? This suggests that immune cell characteristics in
axillary nodes might provide information about how likely it is that a
patient’s cancer comes back. These are intriguing but early results that
need to be confirmed by new and larger studies before it becomes clear
whether regular examination of immune system cells in lymph nodes of
breast cancer patients can tell us which cancers are likely to spread and
thus should be treated more aggressively.
Where Can I Find More Information Online? The following Web sites
contain information on the role of lymph node dissection and
examination in breast cancer.
Breastcancer.org (search for ‘‘lymph node removal’’ and ‘‘sentinel lymph
node dissection’’):
http://www.breastcancer.org
People Living with Cancer (search for ‘‘sentinel lymph node biopsy’’ or
‘‘axillary lymph node’’):
http://www.plwc.org/
Medicineworld.org (search for ‘‘axillary lymph node dissection’’):
http://medicineworld.org/
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